In 1996 and 2000, the US Food and Drug Administration (FDA) approved the use of Nuclear matrix protein 22 (NMP22) as a monitoring tool for predicting the recurrence/clearing of bladder cancer, and for screening undiagnosed individuals who have symptoms of, or are at risk for, that disease.
The fabrication of electrodes for sensing NMP22 and their integration with a portable potentiostat in a homecare system may have great value. This work describes a sensing element comprised of molecularly imprinted polymers (MIPs) for the specific recognition of NMP22 target molecules. Zinc oxide (ZnO) nanorods (214±45nm in diameter and 1. 08±0. 11μm long) were hydrothermally grown on the sensing electrodes to increase the surface area to be coated with MIPs. A portable potentiostat was assembled and a data acquisition (DAQ) card and the Labview program were utilized to monitor electrochemical reaction to sense NMP22 in urine samples. Finally, in phase 0 clinical trials, measurements were made of samples from a few patients with bladder cancer using the NMP22 MIP-coated ZnO nanorods electrodes that were integrated into a portable potentiostat, revealing NMP 22 concentrations in the range 128±19 to 588±53ng/mL.
Biosensors & bioelectronics. 2016 Jan 07 [Epub ahead of print]
Mei-Hwa Lee, James L Thomas, Yu-Chia Chang, Yuh-Shyan Tsai, Bin-Da Liu, Hung-Yin Lin
Department of Materials Science and Engineering, I-Shou University, Kaohsiung 84001, Taiwan. , Department of Physics and Astronomy, University of New Mexico, Albuquerque, NM 87131, USA. , Department of Materials Science and Engineering, I-Shou University, Kaohsiung 84001, Taiwan. , Department of Urology, National Cheng Kung University Hospital, Tainan 70101, Taiwan. , Department of Electrical Engineering, National Cheng Kung University, Tainan 70101, Taiwan. , Department of Chemical and Materials Engineering, National University of Kaohsiung, Kaohsiung 81148, Taiwan.